-Barry E Storer Researcher Activity Profile

Research Author Detailed Information 

Barry E Storer Publication Rate By Year

Barry E Storer has published 2 paper(s) in 2006, 15 paper(s) in 2007, 2 paper(s) in 2008, for a total of 19 research publications in total.

Barry E Be Storer Author Information

LAST NAME: storer

FIRST NAME: Barry E

INITIALS: be

AFFILIATION:

Papers

Barry E Storer's Publication Record

1. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Year Published: 2006
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
2. Pulmonary function in long-term survivors of pediatric hematopoietic cell transplantation. Year Published: 2006
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington Medical School, Seattle, Washington 98109, USA.
3. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Year Published: 2007
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, Seattle, WA 98109, USA. ggeorges@fhcrc.org
4. Hematopoietic stem cell engraftment: a direct comparison between intramarrow and intravenous injection in nonhuman primates. Year Published: 2007
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
5. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Year Published: 2007
6. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Year Published: 2007
Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
7. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Year Published: 2007
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. mmielcar@fhcrc.org
8. Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Year Published: 2007
Department of Biobehavioral Nursing, University of Washington School of Nursing, Seattle, WA, USA.
9. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Year Published: 2007
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
10. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Year Published: 2007
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. mmielcar@fhcrc.org
11. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Year Published: 2007
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. mmielcar@fhcrc.org
12. Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Year Published: 2007
Department of Biobehavioral Nursing, University of Washington School of Nursing, Seattle, WA, USA.
13. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Year Published: 2007
14. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Year Published: 2007
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. mmielcar@fhcrc.org
15. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Year Published: 2007
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA. msorror@fhcrc.org
16. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Year Published: 2008
Stanford University Medical Center, Stanford, California 94305-5623, USA. glaport@stanford.edu
17. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Year Published: 2007
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA. msorror@fhcrc.org
18. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Year Published: 2008
Stanford University Medical Center, Stanford, California 94305-5623, USA. glaport@stanford.edu
19. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. Year Published: 2007
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, Seattle, WA 98109, USA. ggeorges@fhcrc.org